ClinicalTrials.gg
CompletedNCT02412722Updated Feb 28, 2020Results posted

A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies

A Phase 1 interventional study of Sapanisertib and Paclitaxel in Non-hematologic Malignancy, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-28.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purposes of this study are to evaluate the safety and tolerability of sapanisertib (MLN0128) milled active pharmaceutical ingredient (API) capsules administered both as a single agent and in combination with paclitaxel, to characterize the effect of a high-fat meal on the pharmacokinetics (PK) of sapanisertib milled API capsules, and to characterize the PK of sapanisertib milled API capsules when administered on an empty stomach approximately 24 hours after paclitaxel infusion.

Read the detailed description

The drug being tested in this study is called sapanisertib (MLN0128). Sapanisertib is being tested to assess its safety and tolerability when administered alone or in combination with paclitaxel in people who have nonhematologic malignancies. Sapanisertib is also being tested to characterize its PK properties (how is processed by the body) when administered with a high-fat meal compared to on an empty stomach. This study will look at side effects and lab results in people who take sapanisertib with or without paclitaxel.

This open label study enrolled 61 patients. Participants receiving only sapanisertib will participate in a 6-day PK Run-In Period where sapanisertib 4 mg capsules are administered under fasted conditions on Days 1 and 4, and with a high-fat breakfast on Day 3. The main treatment period will begin within 14 days from Day 6 of the PK Run-In Period. In the main treatment period participants will receive sapanisertib 4 mg daily in a 28-day Cycle for up to 12 cycles. Participants in the treatment arm receiving sapanisertib and paclitaxel will not have a PK Run-In Period and will receive sapanisertib 6 mg daily on Days 2-4, 9-11, 16-18, and 23-25 in a 28-day Cycle for up to 12 cycles and paclitaxel 80 mg/m\^2 intravenously (IV) on Days 1, 8, and 15 in 28-day Cycle, for up to 12 cycles. The dose of sapanisertib may be modified based on safety and tolerability during each 28-day cycle in either treatment arm.

This multi-centre trial will be conducted in the United States. The overall time to participate in this study is up to 15 months. Participants in the sapanisertib only arm will make up to 32 visits to the clinic and participants in the sapanisertib and paclitaxel arm will make up to 26 visits to the clinic. All participants will make a final visit to the clinic 30 days after the last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Non-hematologic Malignancy

Keywords

  • Drug therapy
03

In context

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age is ≥ 18 years, including males and females.
  2. Has Advanced nonhematologic , with the exception of primary brain tumor, and have failed or are not eligible for standard of care therapy. History of may be allowed if all the following criteria are met: brain metastases have been treated, there is no evidence of progression or hemorrhage after treatment, dexamethasone discontinued for ≥ 4 weeks before first study drug administration, and there is no ongoing requirement for dexamethasone or anti-epileptic drugs.
  3. Has received not more than 4 prior lines of systemic cytotoxic chemotherapy for advanced or disease.
  4. Has (ECOG) Performance Status 0 to 1.
  5. Has adequate organ function, including the following:

    • Bone marrow reserve consistent with (ANC) ≥ 1.5 x 10\^9/L; count ≥ 100 x 10\^9/L; and ≥ 9 g/dL without transfusion in the last 2 weeks
    • Hepatic: total ≤ 1.5 x the (ULN), transaminases ( [AST]/serum glutamic oxaloacetic transaminase [SGOT] and alanine aminotransferase [ALT]/serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases are present)
    • Renal: normal serum creatinine or calculated ≥ 60 mL/min based either on Cockcroft-Gault estimate or based on urine collection (12- or 24-hour)
    • Metabolic: fasting serum glucose (≤ 130 mg/dL) and fasting triglycerides ≤ 300 mg/dL
  6. Has (LVEF) within 5 absolute percentage points of institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks before first study drug administration (ie, if the institutional normal is 50%, participant's LVEF may be as low as 45% to be eligible for the study).
  7. Is a female participants who:

    • Are for at least 1 year before the screening visit, OR
    • Are surgically sterile, OR
    • If they are of , agree to practice 2 effective methods of , at the same time, from the time of signing the form through 90 days after the last dose of study drug, or
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)

    Male participants, even if surgically sterilized (ie, status postvasectomy), who:

    • Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, or
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the female partner] and withdrawal are not acceptable methods of contraception.)
  8. Has ability to swallow oral medications.
  9. Has voluntary written consent obtained before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.

Exclusion criteria

Exclusion Criteria:

  1. Has a diagnosis of primary brain tumor.
  2. Has untreated or history of or spinal cord compression.
  3. Has failed to recover from the reversible effects of prior anticancer therapies with the exception of alopecia, and after-effects associated with prior tyrosine kinase inhibitor therapy, such as hair depigmentation, hypothyroidism, and/or splinter hemorrhage.
  4. Has received prior cancer therapy or other therapy within 2 weeks before the first administration of study drug. For prior therapies with a half-life longer than 3 days, the interval must be at least 28 days before the first administration of study drug, and the participant must have documented disease progression.
  5. Has initiation of hematopoietic growth factors within 1 week before the first administration of any study drug; participants already receiving hematopoietic growth factors on a chronic basis for ≥ 4 weeks are eligible.
  6. Has chronic systemic (except inhalers) use within 1 week before the first administration of study drug. Premedication with dexamethasone before paclitaxel administration in this study is allowed.
  7. Has manifestations of malabsorption due to prior gastrointestinal surgery, gastrointestinal disease, or for an unknown reason that may alter the absorption of MLN0128.
  8. Has poorly controlled diabetes mellitus defined as glycosylated () > 7%; participants with a history of transient glucose intolerance due to corticosteroid administration are allowed if all other eligibility criteria are met.
  9. Has other comorbidities, such as uncontrolled pulmonary disease, active central nervous system disease, active infection, or any other condition that could compromise the participant's participation in the study.
  10. Has a known infection.
  11. Is pregnant (positive serum or urine pregnancy test) or breastfeeding.
  12. Has any history of unstable angina, myocardial infarction, Class III or IV heart failure, and/or pulmonary hypertension.
  13. Has significant active cardiovascular disease including:

    • Uncontrolled high blood pressure (ie, systolic blood pressure > 180 mmHg, diastolic blood pressure > 95 mmHg)
    • Grade 3 or higher valvular disease
    • Grade 3 or higher atrial fibrillation
    • Grade 3 or higher bradycardia
    • Endocarditis
    • Pulmonary embolism
    • Recent cerebrovascular accident/ ≤ 6 months before enrollment
  14. Diagnosed or treated for another within 2 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  15. Single-Agent QD Arm participants participating in the pharmacokinetic (PK) Run-In (only): participants who use proton pump inhibitors (PPIs) less than 5 days before the first MLN0128 PK Run-In dose OR use H2 receptor antagonists within 24 hours of the first PK Run-In dose.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Single-Agent QD Arm: Sapanisertib 3 mg

    Following Pharmacokinetic (PK) - Run in Period, sapanisertib 3 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, starting from Cycle 2 for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.

    Drug: Sapanisertib

  • Experimental
    Single-Agent QD Arm: Sapanisertib 4 mg

    Following PK Run-In Period, sapanisertib 4 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, for up to 13 cycles.

    Drug: Sapanisertib

  • Experimental
    Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2

    Sapanisertib 4 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 12 cycles, and paclitaxel 80 mg/m\^2, intravenously (IV), on Days 1, 8, and 15 in 28-day Cycle, for up to 6 cycles.

    Drug: Sapanisertib · Drug: Paclitaxel

  • Experimental
    Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2

    Sapanisertib 6 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 9 cycles, and paclitaxel 80 mg/m\^2, IV, on Days 1, 8, and 15 in 28-day Cycle, for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.

    Drug: Sapanisertib · Drug: Paclitaxel

  • Experimental
    Single-Agent QW Arm: Sapanisertib 20 mg

    Sapanisertib 20 mg, capsules milled API, QW in a 28-day Cycle, for up to 6 cycles.

    Drug: Sapanisertib

  • Experimental
    Single-Agent QW Arm: Sapanisertib 30 mg

    Sapanisertib 30 mg, capsules, milled API, QW in a 28-day Cycle, for up to 10 cycles.

    Drug: Sapanisertib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: From Day 1, Cycle 1 through 30 days after the last dose of study drug (up to 15 months)

  2. Geometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled Active Pharmaceutical Ingredient (API) Capsules Under Fasted and Fed Conditions

    Time frame: Days 3 and 5 predose and at multiple time points (up to 24 hours) post-dose

  3. Geometric Mean Ratio of AUC(0-last): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration of Sapanisertib Milled API Capsules Under Fasted and Fed Conditions

    Time frame: Days 3 and 5 predose and at multiple time points (up to 24 hours) post-dose

  4. Geometric Mean Ratio of AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib Milled API Capsules Under Fasted and Fed Conditions

    Time frame: Days 3 and 5 predose and at multiple time points (up to 24 hours) post-dose

  5. Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion

    Time frame: Cycle 1, Day 2 pre-dose and at multiple time points (up to 8 hours) post-dose

  6. Tmax: Time to Reach the Maximum Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion

    Time frame: Cycle 1, Day 2 pre-dose and at multiple time points (up to 8 hours) post-dose

  7. AUC(0-8): Area Under the Plasma Concentration Curve From Time Zero to 8 Hours Post-dose for Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion

    Time frame: Cycle 1, Day 2 pre-dose and at multiple time points (up to 8 hours) post-dose

Secondary outcomes

  1. Geometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions

    Time frame: Days 1 and 3 pre-dose and at multiple time points (up to 24 hours) post-dose

  2. Geometric Mean Ratio of AUC(0-last): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration for Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions

    Time frame: Days 1 and 3 pre-dose and at multiple time points (up to 24 hours) post-dose

  3. AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions

    Time frame: Days 1 and 3 pre-dose and at multiple time points (up to 24 hours) post-dose

  4. Overall Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST)

    ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.

    Time frame: Baseline then every 2 cycles beginning at Cycle 3, Day 1, until disease progression, death or end of study (Up to 14 months)

  5. Progression Free Survival (PFS)

    PFS is defined as the time from the date of first study drug administration to the date of first documented PD or death due to any cause. PD was based on response evaluation criteria in solid tumors (RECIST V1.1), defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Baseline then every 2 cycles beginning at Cycle 3, Day 1, until disease progression, death or end of study (Up to 14 months)

  6. Clinical Benefit Response (CBR)

    CBR is defined as the percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD) using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD is neither shrinkage by greater than or equal to 30% of the sum of the longest diameter of target lesions or the increase of lesions by greater than or equal to 20% of the sum of the longest diameter of target lesions.

    Time frame: Baseline then every 2 cycles beginning at Cycle 3, Day 1, until disease progression, death or end of study (Up to 14 months)

  7. Change From Baseline in Tumor Volume/Size

    Changes in tumor size and volume will be determined by measurements from computed tomography (CT) and magnetic resonance imaging (MRI) scans.

    Time frame: From Cycle 1 Day -14 to 14 months

07

Results

Posted Feb 28, 2020

Participant flow

Participants took part in the study at 4 investigative sites in United States from 26 March 2015 to 31 May 2018.

Participant flow — Overall Study
MilestoneSingle-Agent QD Arm: Sapanisertib 3 mgSingle-Agent QD Arm: Sapanisertib 4 mgCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2Single-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mg
Started118715713
Safety population116715713
Completed000000
Not completed118715713
Withdrew: Adverse event020303
Withdrew: Progressive disease644933
Withdrew: Withdrawal by subject201211
Withdrew: Lost to follow-up000010
Withdrew: Received drug in run-in and discontinued020000
Withdrew: Reason not specified302126

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
From Day 1, Cycle 1 through 30 days after the last dose of study drug (up to 15 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPK-Run In Period Fasted (Unmilled)PK-Run In Period Fed (Milled)PK-Run In Period Fasted (Milled)Single-Agent QD Arm: Sapanisertib 3 mgSingle-Agent QD Arm: Sapanisertib 4 mgCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2Single-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mg
At least one AE769116714613
Serious AE102322747
PrimaryGeometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled Active Pharmaceutical Ingredient (API) Capsules Under Fasted and Fed Conditions
Time frame:
Days 3 and 5 predose and at multiple time points (up to 24 hours) post-dose
Reported as:
Geometric mean · ng/mL
Geometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled Active Pharmaceutical Ingredient (API) Capsules Under Fasted and Fed Conditions
ng/mLSapanisertib 4 mg Milled Capsules Under Fed ConditionsSapanisertib 4 mg Milled Capsules Under Fasted Conditions
Geometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled Active Pharmaceutical Ingredient (API) Capsules Under Fasted and Fed Conditions21.6 ± 37.436.4 ± 50.6
Statistical analysis
  • Sapanisertib 4 mg Milled Capsules Under Fed Conditions vs Sapanisertib 4 mg Milled Capsules Under Fasted Conditions · Geometric mean ratio: 0.59 · 90% CI 0.46 to 0.76
PrimaryGeometric Mean Ratio of AUC(0-last): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration of Sapanisertib Milled API Capsules Under Fasted and Fed Conditions
Time frame:
Days 3 and 5 predose and at multiple time points (up to 24 hours) post-dose
Reported as:
Geometric mean · ng*hr/mL
Geometric Mean Ratio of AUC(0-last): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration of Sapanisertib Milled API Capsules Under Fasted and Fed Conditions
ng*hr/mLSapanisertib 4 mg Milled Capsules Under Fed ConditionsSapanisertib 4 mg Milled Capsules Under Fasted Conditions
Geometric Mean Ratio of AUC(0-last): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration of Sapanisertib Milled API Capsules Under Fasted and Fed Conditions205.9 ± 59.8229.2 ± 58.2
Statistical analysis
  • Sapanisertib 4 mg Milled Capsules Under Fed Conditions vs Sapanisertib 4 mg Milled Capsules Under Fasted Conditions · Geometric mean ratio: 0.90 · 90% CI 0.59 to 1.36
PrimaryGeometric Mean Ratio of AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib Milled API Capsules Under Fasted and Fed Conditions
Time frame:
Days 3 and 5 predose and at multiple time points (up to 24 hours) post-dose
Reported as:
Geometric mean · ng*hr/mL
Geometric Mean Ratio of AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib Milled API Capsules Under Fasted and Fed Conditions
ng*hr/mLSapanisertib 4 mg Milled Capsules Under Fed ConditionsSapanisertib 4 mg Milled Capsules Under Fasted Conditions
Geometric Mean Ratio of AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib Milled API Capsules Under Fasted and Fed Conditions382.8 ± 64.7369.2 ± 50.0
Statistical analysis
  • Sapanisertib 4 mg Milled Capsules Under Fed Conditions vs Sapanisertib 4 mg Milled Capsules Under Fasted Conditions · Geometric mean ratio: 1.04 · 90% CI 0.72 to 1.49
PrimaryCmax: Maximum Observed Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion
Time frame:
Cycle 1, Day 2 pre-dose and at multiple time points (up to 8 hours) post-dose
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion
ng/mLCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2
Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion35.2 ± 22.3371.4 ± 29.16
PrimaryTmax: Time to Reach the Maximum Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion
Time frame:
Cycle 1, Day 2 pre-dose and at multiple time points (up to 8 hours) post-dose
Reported as:
Median · hours
Tmax: Time to Reach the Maximum Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion
hoursCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2
Tmax: Time to Reach the Maximum Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion2.2 (0.9 to 5.6)1.1 (0.5 to 3.0)
PrimaryAUC(0-8): Area Under the Plasma Concentration Curve From Time Zero to 8 Hours Post-dose for Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion
Time frame:
Cycle 1, Day 2 pre-dose and at multiple time points (up to 8 hours) post-dose
Reported as:
Mean · ng*hr/mL
AUC(0-8): Area Under the Plasma Concentration Curve From Time Zero to 8 Hours Post-dose for Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion
ng*hr/mLCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2
AUC(0-8): Area Under the Plasma Concentration Curve From Time Zero to 8 Hours Post-dose for Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion144.8 ± 84.15260.6 ± 89.59
SecondaryGeometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions
Time frame:
Days 1 and 3 pre-dose and at multiple time points (up to 24 hours) post-dose
Reported as:
Geometric mean · ng/mL
Geometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions
ng/mLSapanisertib 4 mg Milled Capsules Under Fasted ConditionsSapanisertib 4 mg Unmilled Capsules Under Fasted ConditionsSingle-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mg
Geometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions36.4 ± 50.634.0 ± 48.1208.6 ± 17.3235.2 ± 43.4
Statistical analysis
  • Sapanisertib 4 mg Milled Capsules Under Fasted Conditions vs Sapanisertib 4 mg Unmilled Capsules Under Fasted Conditions · Geometric mean ratio: 1.07 · 90% CI 0.78 to 1.47
SecondaryGeometric Mean Ratio of AUC(0-last): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration for Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions
Time frame:
Days 1 and 3 pre-dose and at multiple time points (up to 24 hours) post-dose
Reported as:
Geometric mean · hr*ng/mL
Geometric Mean Ratio of AUC(0-last): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration for Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions
hr*ng/mLSapanisertib 4 mg Milled Capsules Under Fasted ConditionsSapanisertib 4 mg Unmilled Capsules Under Fasted ConditionsSingle-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mg
Geometric Mean Ratio of AUC(0-last): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration for Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions229.2 ± 58.2204.6 ± 57.31238.1 ± 53.31528.8 ± 43.5
Statistical analysis
  • Sapanisertib 4 mg Milled Capsules Under Fasted Conditions vs Sapanisertib 4 mg Unmilled Capsules Under Fasted Conditions · Geometric mean ratio: 1.12 · 90% CI 0.75 to 1.68
SecondaryAUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions
Time frame:
Days 1 and 3 pre-dose and at multiple time points (up to 24 hours) post-dose
Reported as:
Geometric mean · hr*ng/mL
AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions
hr*ng/mLSapanisertib 4 mg Milled Capsules Under Fasted ConditionsSapanisertib 4 mg Unmilled Capsules Under Fasted ConditionsSingle-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mg
AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib Milled Versus Unmilled API Capsules Under Fasted Conditions369.2 ± 50.0400.8 ± 48.21326.2 ± 61.51636.6 ± 45.2
Statistical analysis
  • Sapanisertib 4 mg Milled Capsules Under Fasted Conditions vs Sapanisertib 4 mg Unmilled Capsules Under Fasted Conditions · Geometric mean ratio: 0.92 · 90% CI 0.67 to 1.26
SecondaryOverall Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST)

ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.

Time frame:
Baseline then every 2 cycles beginning at Cycle 3, Day 1, until disease progression, death or end of study (Up to 14 months)
Reported as:
Number · percentage of participants
Overall Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST)
percentage of participantsSingle-Agent QD Arm: Sapanisertib 3 mgSingle-Agent QD Arm: Sapanisertib 4 mgCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2Single-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mg
Overall Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST)9.116.714.320.00.00.0
SecondaryProgression Free Survival (PFS)

PFS is defined as the time from the date of first study drug administration to the date of first documented PD or death due to any cause. PD was based on response evaluation criteria in solid tumors (RECIST V1.1), defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Baseline then every 2 cycles beginning at Cycle 3, Day 1, until disease progression, death or end of study (Up to 14 months)

No measurements were reported for this outcome.

SecondaryClinical Benefit Response (CBR)

CBR is defined as the percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD) using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD is neither shrinkage by greater than or equal to 30% of the sum of the longest diameter of target lesions or the increase of lesions by greater than or equal to 20% of the sum of the longest diameter of target lesions.

Time frame:
Baseline then every 2 cycles beginning at Cycle 3, Day 1, until disease progression, death or end of study (Up to 14 months)
Reported as:
Number · percentage of participants
Clinical Benefit Response (CBR)
percentage of participantsSingle-Agent QD Arm: Sapanisertib 3 mgSingle-Agent QD Arm: Sapanisertib 4 mgCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2Single-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mg
CR+PR+SD63.633.342.953.342.946.2
CR + PR + SD (>= 6 Months)36.433.314.326.70.07.7
SecondaryChange From Baseline in Tumor Volume/Size

Changes in tumor size and volume will be determined by measurements from computed tomography (CT) and magnetic resonance imaging (MRI) scans.

Time frame:
From Cycle 1 Day -14 to 14 months

No measurements were reported for this outcome.

Adverse events

Collected over From first dose of study drug up to 30 days post last dose (Up to 15 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PK-Run In Period Fasted (Unmilled)0/19 (0%)1/19 (5.3%)7/19 (36.8%)
PK-Run In Period Fed (Milled)0/19 (0%)0/19 (0%)6/19 (31.6%)
PK-Run In Period Fasted (Milled)0/17 (0%)2/17 (11.8%)9/17 (52.9%)
Single-Agent QD Arm: Sapanisertib 3 mg0/11 (0%)3/11 (27.3%)11/11 (100%)
Single-Agent QD Arm: Sapanisertib 4 mg1/6 (16.7%)2/6 (33.3%)6/6 (100%)
Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^20/7 (0%)2/7 (28.6%)7/7 (100%)
Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^21/15 (6.7%)7/15 (46.7%)14/15 (93.3%)
Single-Agent QW Arm: Sapanisertib 20 mg0/7 (0%)4/7 (57.1%)6/7 (85.7%)
Single-Agent QW Arm: Sapanisertib 30 mg1/13 (7.7%)7/13 (53.8%)12/13 (92.3%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventPK-Run In Period Fasted (Unmilled)PK-Run In Period Fed (Milled)PK-Run In Period Fasted (Milled)Single-Agent QD Arm: Sapanisertib 3 mgSingle-Agent QD Arm: Sapanisertib 4 mgCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2Single-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mg
HypotensionVascular disorders0/190/190/170/110/60/71/152/70/13
Blood creatinine increasedInvestigations1/190/190/170/111/60/71/150/70/13
Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/190/190/170/111/60/70/150/70/13
HyperglycaemiaMetabolism and nutrition disorders0/190/190/170/110/60/70/150/72/13
Cardiac failure congestiveCardiac disorders0/190/190/170/110/60/70/151/70/13
Abdominal painGastrointestinal disorders0/190/190/171/110/61/71/151/71/13
DysphagiaGastrointestinal disorders0/190/190/170/110/60/70/151/70/13
Intestinal obstructionGastrointestinal disorders0/190/190/170/110/60/70/151/70/13
Enterococcal sepsisInfections and infestations0/190/190/170/110/60/70/151/70/13
Tracheal obstructionInjury, poisoning and procedural complications0/190/190/170/110/60/70/151/70/13
Most frequent other events
Showing 10 of 193
Most frequent other events
EventPK-Run In Period Fasted (Unmilled)PK-Run In Period Fed (Milled)PK-Run In Period Fasted (Milled)Single-Agent QD Arm: Sapanisertib 3 mgSingle-Agent QD Arm: Sapanisertib 4 mgCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2Single-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mg
NauseaGastrointestinal disorders2/190/191/175/111/65/76/154/76/13
DiarrhoeaGastrointestinal disorders0/190/190/172/114/65/78/154/72/13
FatigueGeneral disorders0/190/191/176/114/62/79/153/78/13
StomatitisGastrointestinal disorders0/190/190/171/112/64/74/150/72/13
PruritusSkin and subcutaneous tissue disorders0/190/190/176/113/60/70/150/71/13
VomitingGastrointestinal disorders4/191/192/173/111/62/75/152/77/13
Decreased appetiteMetabolism and nutrition disorders1/190/190/174/112/63/78/152/72/13
Neuropathy peripheralNervous system disorders0/190/190/170/110/63/72/150/70/13
Rash maculo-papularSkin and subcutaneous tissue disorders0/190/190/174/110/62/70/150/72/13
Upper respiratory tract infectionInfections and infestations0/190/190/170/112/61/70/150/71/13

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Single-Agent QD Arm: Sapanisertib 3 mgSingle-Agent QD Arm: Sapanisertib 4 mgCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2Single-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mgTotal
Mean62.5 ± 15.7660.5 ± 8.1756.2 ± 7.7563.4 ± 12.7457.0 ± 16.4560.5 ± 12.0260.7 ± 12.47
Sex: Female, Male
Sex: Female, Male(Participants)Single-Agent QD Arm: Sapanisertib 3 mgSingle-Agent QD Arm: Sapanisertib 4 mgCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2Single-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mgTotal
Female9651131044
Male22244317
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single-Agent QD Arm: Sapanisertib 3 mgSingle-Agent QD Arm: Sapanisertib 4 mgCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2Single-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mgTotal
Hispanic or Latino0001001
Not Hispanic or Latino11871461258
Unknown or Not Reported0000112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single-Agent QD Arm: Sapanisertib 3 mgSingle-Agent QD Arm: Sapanisertib 4 mgCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2Single-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mgTotal
American Indian or Alaska Native1001002
Asian0000112
Native Hawaiian or Other Pacific Islander0000000
Black or African American1112117
White9761151149
More than one race0000000
Unknown or Not Reported0001001
Region of Enrollment
Region of Enrollment(Participants)Single-Agent QD Arm: Sapanisertib 3 mgSingle-Agent QD Arm: Sapanisertib 4 mgCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2Single-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mgTotal
United States11871571361
Height
Height(cm)Single-Agent QD Arm: Sapanisertib 3 mgSingle-Agent QD Arm: Sapanisertib 4 mgCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2Single-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mgTotal
Mean163.9 ± 7.78168.0 ± 8.52170.2 ± 6.68166.0 ± 11.43165.3 ± 11.92164.4 ± 5.05165.9 ± 8.76
Weight
Weight(kg)Single-Agent QD Arm: Sapanisertib 3 mgSingle-Agent QD Arm: Sapanisertib 4 mgCombination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2Single-Agent QW Arm: Sapanisertib 20 mgSingle-Agent QW Arm: Sapanisertib 30 mgTotal
Mean71.2 ± 17.0274.4 ± 14.1187.2 ± 35.2375.3 ± 27.4563.3 ± 15.5561.8 ± 11.1071.6 ± 21.96
08

Study locations

5 sites
  • Scottsdale, Arizona, United States
  • Sarasota, Florida, United States
  • Oklahoma City, Oklahoma, United States
  • Germantown, Tennessee, United States
  • Nashville, Tennessee, United States
09

References and documents

Publications

  • Chopra M. Annual Congress of the European Society for Medical Oncology (ESMO): Copenhagen, Denmark; 7-11 October 2016. Target Oncol. 2016 Dec;11(6):705-709. doi: 10.1007/s11523-016-0464-3. No abstract available. PubMed 27812901 ↗
  • Moore KN, Bauer TM, Falchook GS, Chowdhury S, Patel C, Neuwirth R, Enke A, Zohren F, Patel MR. Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. ESMO Open. 2018 Feb 1;3(2):e000291. doi: 10.1136/esmoopen-2017-000291. eCollection 2018. PubMed 29464110 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in May 2018, 38 months.

Results were first posted in Feb 2020, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2015
First posted
Apr 9, 2015
StartActual
Mar 26, 2015
Primary completionActual
May 31, 2018
CompletionActual
May 31, 2018
Results first posted
Feb 28, 2020
Last update
Feb 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02412722
Responsible party
Sponsor
First posted
Apr 9, 2015
Start date
Mar 26, 2015
Primary completion
May 31, 2018
Completion
May 31, 2018
Results posted
Feb 28, 2020
Last update
Feb 28, 2020

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion